11.01.01
As we close out 2001 and head into 2002, some say the nutraceuticals industry faces an uphill battle in the face of a struggling economy, the aftermath of September 11 and dwindling consumer confidence. That said, many segments of the business continue to do well and many executives are positive about the future of specific product categories. Increased emphasis on science and credibility appears to be the focus on the supplement side of the business, while in the functional food and beverage area, new product introductions continue and consumer interest remains high. What follows is a look-from executives throughout the industry-at the year gone by and the year to come.
"Once again the industry has experienced a difficult year and we can look forward to more of the same in '02. Although glucosamine and calcium continue to power along, there have been few big new products. The disappointments in the functional food arena continue. We can expect to see more M&A activity as big companies look to ease their way into the space. The recent deals between Danone and Stonyfield Farm and Johnson & Johnson acquiring Viactiv from Mead Johnson are two different ex
"Once again the industry has experienced a difficult year and we can look forward to more of the same in '02. Although glucosamine and calcium continue to power along, there have been few big new products. The disappointments in the functional food arena continue. We can expect to see more M&A activity as big companies look to ease their way into the space. The recent deals between Danone and Stonyfield Farm and Johnson & Johnson acquiring Viactiv from Mead Johnson are two different ex
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
